Powered by

Vifor Pharma's Phase-II AMBER Study Meets Primary Endpoint

May 10, 2019 - Business Wire

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190510005469/en/

Vifor Pharma today announced results from the phase-II AMBER study which demonstrated that a significantly higher proportion of patients with resistant hypertension (RHTN) and chronic kidney disease (CKD) taking Veltassa® (patiromer) remained on spironolactone therapy compared to patients taking placebo at week 12. Veltassa® was shown to ena...